Compare Novavax Inc (NVAX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Royal Bank of Canada — how do they compare? Novavax Inc trades at $12.83 (market cap $1.82B), while Royal Bank of Canada trades at $191.98 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 144.5× Novavax Inc's market cap, and Royal Bank of Canada pays a 2.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Royal Bank of Canada for 47 Days on average.
| NVAX | RY | |
|---|---|---|
Market Cap | $1.82B | $262.99B |
Volume | 6,198,505 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $12.56 | $217.87 |
52-Week Low | $6.22 | $143.64 |
Typical Hold Time | 59 Days | 47 Days |
Enterprise Value | $1.39B | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Royal Bank of Canada (RY) trades at $191.33, up 0.06% on the day, with a bearish technical signal and key support at $189. The company reported strong earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS of $3.07 versus $2.89 expected. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Analyst sentiment is mixed, with 43% buy ratings but technical indicators showing selling pressure.
RY's outlook is supported by solid profitability and dividend payments, but faces risks from stretched valuations and negative cash flow trends. The stock's current bearish technical stance and high debt levels warrant caution, though institutional interest remains. Upside depends on sustained earnings growth and effective cost management amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
